熱門資訊> 正文
Labcorp扩大PathAI合作伙伴关系,在全国部署数字病理平台
2026-02-23 20:27
- Labcorp (LH) on Monday said it will expand its collaboration with PathAI to deploy the FDA-cleared AISight Dx digital pathology platform across its national network of anatomic pathology labs and hospital collaborations.
- Labcorp said the cloud-based platform will support fully digital workflows for slide review, case management and collaboration, and integrate AI-powered image analysis to assist in diagnostics.
- The company said it will also incorporate digital pathology workflows to support its precision medicine products.
- The expansion builds on Labcorp’s 2019 strategic investment in PathAI and follows ongoing collaboration in AI-driven clinical trial support and validation of AI-pathology solutions.
- LH +1.59% premarket to $287.17.
- Source: Press Release
More on Labcorp Holdings
- Labcorp Holdings Inc. (LH) Q4 2025 Earnings Call Transcript
- Labcorp Holdings Inc. 2025 Q4 - Results - Earnings Call Presentation
- Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Labcorp outlines 5.4% midpoint revenue growth and 9% EPS target for 2026 while advancing specialty and AI initiatives
- Labcorp slips after Q4 revenue miss
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。